Introduction
Henoch-Schonlein Purpura is a systemic vasculitis characterizedclinicalIyby palpable purpura, arthritis with renal and gastrointestinal involvement and, histologicalIy, by immunodeposition of IgA-containing immune complexes in the skin or kidney. Such disease is more common in children with an incidence of 15/20 cases/lOO.OOO childrenlper year [Nielsen 1988 ]. In adults, the incidence of renal involvementranges from 45 -85% of cases [Coppo et al. 1999] . There is some debate regarding the different clinical course between adults and children. Indeed, a study showed that clinical presentation, renal lesions and long-term outcome were the same among adult and pediatric patients with HSP and renal involvement [Coppo et al. 1999 ], while, another study, which observed retrospectively 250 adults on an average of 14.8 years, showed that clinical presentation in adults was more severe and the outcome was poorerthan in children [PilIeboutet al. 2002] .
Pathogenesis is stilI unknown, however, an infection involving the mucosal system of the upper respiratory tract has been reported as a likely cause of the ilIness [Miura et al. 1992] . Another possible cause is the association with drug ingestion [Borras-Blasco et al. 2003 ]. Here, we presenta case ofan adultpatient who developed a drug-related HenochSchonlein purpura.
Case report
In August 2004, a 69-year-old man was adrnitted to our hospital with microscopic hematuria, proteinuria and acuterenal failure.
2 months before admission he was diagnosed with purpuric rash with an unconfirmed association with drug ingestion (ketorolac-trometarnine).The patient stated he had taken several drugs, and the onset of purpuric rash had occurred a few days after ingesting ketorolac. At that time, urine analysis showed microscopic hematuria with normal renal function. The purpuric rash did not disappear on withdrawal of ketorolac. On admission, physical examination revealed persistence of multiple confluentpurpuric lesion on the legs, In sucha clinicalsetting,the immunecomplex process is indicative of Henoch-Schonleinpurpura nephritis. The patient was treated with boluses of methylprednisone (750 mg) for 3 days followedby a combination of prednisone (0.5 mg/kg/day) and cyclophosphamide (125mg/day). 1year later,due to cervical arthrosis,he started therapy with coefferalgan (1.5 g/day of acetaminophen and 90 mg/day of codeine phosphate). After l week, the patient presented with gross hematuria, arthralgias in the knees, wrists and elbows, and extensive bilaterally petechial hemorrhages on the arms and legs. On admission, temperature was 39.5°C and blood pressure was normal. Laboratory testing revealed creatinine 2.7 mg/dl, hematocrit 30.5%, white blood cell count 13,51O/mm3(N 87%), platelet count 257,000/mm3, 24-hour proteinuria 0.95 g. Urine sediment showed macroscopic hematuria (severe dysmorphic erythrocytes). C-reactive protein level was 375 mg/l. Serum IgA, IgG, IgM were normal. Serum complement was normal. Antinuclear antibodies were negative. Antineutrophilic cytoplasmic antibodies (cytoplasmic pattem), antineutrophilic cytoplasmic antibodies (perinuclear pattem) and anti-DNAantibodies were negative. Cryoglobulins were negative. Co-efferalgan was discontinued. Gross hematuria and the purpuric rash disappeared and renal function returned to normal after 2 weeks. On the last examination, 9 months later; serum creatinine was 0.9mg/dlandproteinuriawas 0.125g/24h.
Discussion
The involvement of renal disease in HSP may vary [Cameron 1984] .Most patients may .
have renal disease characterizedby hematuria and proteinuria, with slightly elevated serum creatinine. However, in some patients, nephritic syndrome and/or acute renal failure may occur [BIanco et al. 1997] . Clinical remission is not common in patients with HSP and, as Pillebout observed, it was achieved in only 20% out of250 adult patients [Pillehout et al. 2002] . Factors associated with a poor prognosis, like high degree of proteinuria, renal failure, high percentage of sclerotic glomeruli, fibrinoid necrosis and interstitial fibrosis were mildly present in our patient.
Several drugs are associated with onset of HSP. In Table l , HSPs associated with drugs ingestion are listed. Sincemost drugs are antibiotics, we could also deduce that infection may play a role in the pathogenesis ofHSP in these cases. Other drugs include antihypertensive such as enalapril or losartan, metoclopramide, ranitidine, streptokinase, acetylsalicylic acid, acenocoumarol and thalidomide.
In 1987, a case of HSP associated with Co-dydramol (acetaminophen plus dihydrocodeine tartrate) ingestion was reported [Naranjo et al. 1981] . From a careful reading of this case report we deduced that the diagnosis of HSP could be questioned. Indeed, the symptoms ofthe patient, in Richards and colleagues' case report, were characterized by purpuric rash on the feet, legs, abdomen and arms, joint pains and ankle and foot edema, without carrying out immunofluorescence studies [Richards and Linley 1987] .
IgA immunodeposition, either in the skin or kidney, is necessary for HSP diagnosis [Cameron 1984] . In addition to IgA immunodeposition,their patient didn't show any clear sign ofrenal involvement, since there was no evidence of hematuria, proteinuria or renal failure, and the only evidence of renal disease was the presence of edema. Considering all these factors, other diagnoses could have been made such as hypersensivity vasculitis, mixed essential cryoglobulinemia, microscopie polyangiitis, acutepost-streptococcal glomerulonephritis and endovascular infection [Michel et al. 1992, Richards and Linley 1987] .
The different renal involvement in the 2 episodes is relevant. Indeed, in the first episode, renal failure was mild and only microhematuria was observed, whilst the relapse was characterizedby rapidly progressive glomerulonephritis with gross hematuria. In the last episode, the evolution towards end-stage renal disease was arrested due to discontinuation of drug (acetaminophen/codeine) intake.
The occurrence of HSP was probably related to the consumption of acetaminophen and codeine for many reasons, even if another pathogenetic mechanism cannot be ruled out. First of all, there was a close temporal relationship between drug ingestion and onset of symptoms. Moreover, co-efferalgan (acetaminophen and codeine) was the only drug added before the onset of cutaneous, renai andjoint symptoms, and when its intake was interrupted, the patient's generaI condition improved. For this reason, in accordance with our data and on the basis ofthe Naranjo algorithm, adverse drug reaction could be considered possible [Habib et al. 1993] .
It has to be mentioned that our patient had taken acetaminophen several times in the past, whilst he denied he had taken codeine in the past. Therefore, we deduced that codeine intake, or the combination ofboth molecules, may be responsible for adverse drug reaction. Drug rechallenge was not attempted for ethical reasons, since, with the available data, adverse drug reaction could be considered possible.
For this reason, we believe that our patient may represent the first clear evidence of a possible relation between HSP and acetaminophen/codeine consumption.
Clinicians should be aware ofpossible associations between HSP and acetaminophen and/or codeine consumption in order to provide prompt therapeutic intervention, including drug intake discontinuation.
